Effect of vitamin E and memantine on functional decline
in Alzheimer disease: the TEAM-AD VA Cooperative Randomized trial.
For example, weight loss may be a risk factor of functional decline
(the "outcome") for NH residents, whereas it itself is an outcome of NH care.
In addition, two of the three-factor models--specifically, those involving genetic risk with recent functional decline
, unusual thought content, and either suspicion/paranoia or impaired social functioning--had positive predictive values of 74% and 81%, respectively, while no further gain in prediction was associated with any of the four-or five-factor models, according to the authors.
05) suggest demographic differences in the risk of functional decline
A similar argument can be made for the costs associated with functional decline
, impaired mobility and inability to work or perform the daily tasks of living.
It's intriguing to find that loneliness is independently associated with an increased rate of death and functional decline
," said first author Carla Perissinotto, MD, MHS, assistant professor in the UCSF Division of Geriatrics.
These data support an interventional trial evaluating different thresholds of ambulatory systolic blood pressure for preventing white matter progression and functional decline
in older people," said Dr.
Another emerging concept about delirium is that it markedly and independently affects patient outcomes such as length of stay, functional decline
, and loss of independent living.
These findings suggest that Medicare beneficiaries who belong to HMOs experience comparable rates of functional decline
to those experienced by beneficiaries in the FFS sector with similar initial levels of function and health status.
The profiled programs are designed to shore up the critical patient handoffs of hospital-to-home and hospital-to-skilled nursing facility (SNF); identify functional decline
in the elderly (a harbinger of high utilization); and enlist the help of community pharmacists in improving medication adherence.
Key secondary objectives are to evaluate the effect of AD-4833 versus placebo on the progression of cognitive decline and to compare the effects of AD-4833 versus placebo on functional decline
and instrumental activities of daily living.
None of these strategies tested--blocking amyloid, improving insulin sensitivity in the brain, or even doubling up on agents that improve synaptic signaling--was able to alter the steady rate of cognitive and functional decline
in patients with mild to moderate Alzheimer's.